We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+15.65%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$515M
AUM Growth
+$28.6M
Cap. Flow
+$7.92M
Cap. Flow %
1.54%
Top 10 Hldgs %
33.78%
Holding
87
New
22
Increased
22
Reduced
21
Closed
22

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$18.1M
2
BSX icon
Boston Scientific
BSX
+$14M
3
CAH icon
Cardinal Health
CAH
+$12.7M
4
BIIB icon
Biogen
BIIB
+$10.6M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$10.1M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$15.5M
2
LLY icon
Eli Lilly
LLY
+$15.2M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$14.2M
4
ELV icon
Elevance Health
ELV
+$13.3M
5
DXCM icon
DexCom
DXCM
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
51
DELISTED
Ventyx Biosciences
VTYX
$3.49M 0.68%
+100,000
New +$2.21M
LFST icon
52
Lifestance Health
LFST
$4.39B
$3.48M 0.68%
525,000
+149,272
+40% +$1.04M
REPL icon
53
Replimune Group
REPL
$1.15B
$3.45M 0.67%
200,000
-19,194
-9% -$366K
FMTX
54
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$3.31M 0.64%
92,000
-38,051
-29% -$502K
AMED
55
DELISTED
Amedisys
AMED
$3.19M 0.62%
+33,000
New +$3.94M
HRTX icon
56
Heron Therapeutics
HRTX
$61.5M
$2.95M 0.57%
700,000
-300,000
-30% -$1.17M
AGIO icon
57
Agios Pharmaceuticals
AGIO
$1.95B
$2.83M 0.55%
+100,000
New +$2.68M
DSGN icon
58
Design Therapeutics
DSGN
$915M
$2.09M 0.41%
+125,000
New +$2.49M
ARCT icon
59
Arcturus Therapeutics
ARCT
$214M
$1.93M 0.37%
130,000
-26,553
-17% -$446K
HZNP
60
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.86M 0.36%
+30,000
New +$2.1M
CINC
61
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$1.64M 0.32%
50,000
+8,252
+20% +$233K
FOLD
62
DELISTED
Amicus Therapeutics
FOLD
$1.36M 0.26%
130,000
-574,490
-82% -$6.4M
MIRM icon
63
Mirum Pharmaceuticals
MIRM
$5.99B
$1.05M 0.2%
50,000
-127,427
-72% -$3.07M
DNTH icon
64
Dianthus Therapeutics
DNTH
$6.07B
$532K 0.1%
23,563
+3,046
+15% +$83.4K
LBPH
65
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$409K 0.08%
110,000
+52,665
+92% +$195K
AGL icon
66
Agilon Health
AGL
$1.45B
– –
-9,226
Closed -$5.04M
ATRA icon
67
Atara Biotherapeutics
ATRA
$80.6M
– –
-8,350
Closed -$1.63M
AZN icon
68
AstraZeneca
AZN
$246B
– –
-117,415
Closed -$15.5M
DXCM icon
69
DexCom
DXCM
$33.8B
– –
-166,991
Closed -$12.4M
ICLR icon
70
Icon
ICLR
$12.8B
– –
-31,311
Closed -$6.79M
INSM icon
71
Insmed
INSM
$29B
– –
-104,369
Closed -$2.06M
JAZZ icon
72
Jazz Pharmaceuticals
JAZZ
$16.1B
– –
-20,874
Closed -$3.26M
KNSA icon
73
Kiniksa Pharmaceuticals
KNSA
$6.07B
– –
-234,830
Closed -$2.28M
LXRX icon
74
Lexicon Pharmaceuticals
LXRX
$1.08B
– –
-300,000
Closed -$558K
MRNA icon
75
Moderna
MRNA
$24.2B
– –
-40,000
Closed -$5.71M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Integral Health Asset Management held 87 positions worth $515M, up 5.9% from $486M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Integral Health Asset Management's Q3 2022 filing shows 22 new, 22 increased, 21 reduced and 22 closed positions. Its largest new stake was Baxter International: 300,000 shares worth $16.2M. The largest sale was AstraZeneca, an estimated $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • Integral Health Asset Management's largest Q3 2022 buy was Baxter International: 300,000 shares worth $16.2M.
  • Integral Health Asset Management added most to CRISPR Therapeutics in Q3 2022, an estimated $10.1M increase.
  • Integral Health Asset Management's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $15.2M.
  • Integral Health Asset Management fully exited AstraZeneca in Q3 2022, selling an estimated $15.5M.
  • Integral Health Asset Management's ten largest holdings make up 34% of its $515M portfolio in Q3 2022.
  • Integral Health Asset Management opened 22 new positions and closed 22 in Q3 2022.
  • Integral Health Asset Management's portfolio value rose 5.9% quarter-over-quarter to $515M.

Based on Integral Health Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.